Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Halia Therapeutics
Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer’s Prevention in APOE4 Carriers
July 13, 2026
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
June 15, 2026
Halia Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference
May 28, 2026
Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
May 19, 2026
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
May 12, 2026